Eita Fujimoto
7PUBLICATIONS
5CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Feb 16, 2026
Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.Manami Yoneyama, Teppei Hagino, Akihiko Uchiyama
|Feb 11, 2026
Effectiveness of Anti-IL-13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48-Week Outcomes by Lebrikizumab and Tralokinumab.Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama
|Jan 05, 2026
Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study.Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama
|Sep 18, 2025
A 104-Week Real-World Outcome of Bimekizumab Treatment for Psoriasis: Biologic-Naïve Versus -Experienced Patients.Yohei Takahashi, Teppei Hagino, Hidehisa Saeki
|Jul 25, 2025
Transition of Blood Biomarkers During 24-Week Treatment With Lebrikizumab or Tralokinumab in Atopic Dermatitis: A Real-World Analysis Stratified by Prior Systemic Therapy.Teppei Hagino, Akihiko Uchiyama, Keiji Kosaka
|Mar 15, 2025
Long-term maintenance of responses to bimekizumab treatment in moderate-to-severe psoriasis: A real-world comparison of Q4W versus Q8W dosing or bio-naïve versus bio-switched patients.Marina Onda, Teppei Hagino, Hidehisa Saeki
Pageof 2
